{"title":"《柳叶刀-肿瘤》2025年修正；26日:629 - 40","authors":"","doi":"10.1016/s1470-2045(25)00541-8","DOIUrl":null,"url":null,"abstract":"<em>Kuemmel S, Graeser M, Schmid P, et al. Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial.</em> Lancet Oncol <em>2025; <strong>26:</strong> 629–40</em>—In this Article, the first sentence of the fifth paragraph of the Discussion section should have read “Our translational research suggests that higher baseline expression of <em>ERBB2</em>, <em>PD-1</em>, and <em>PD-L1</em>, and ctDNA negativity are associated with pathological complete response after neoadjuvant pembrolizumab plus dual HER2 blockade.” This correction has been made to the online version as of Sept 29, 2025.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"141 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Oncol 2025; 26: 629–40\",\"authors\":\"\",\"doi\":\"10.1016/s1470-2045(25)00541-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<em>Kuemmel S, Graeser M, Schmid P, et al. Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial.</em> Lancet Oncol <em>2025; <strong>26:</strong> 629–40</em>—In this Article, the first sentence of the fifth paragraph of the Discussion section should have read “Our translational research suggests that higher baseline expression of <em>ERBB2</em>, <em>PD-1</em>, and <em>PD-L1</em>, and ctDNA negativity are associated with pathological complete response after neoadjuvant pembrolizumab plus dual HER2 blockade.” This correction has been made to the online version as of Sept 29, 2025.\",\"PeriodicalId\":22865,\"journal\":{\"name\":\"The Lancet Oncology\",\"volume\":\"141 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s1470-2045(25)00541-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1470-2045(25)00541-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Kuemmel S, Graeser M, Schmid P, et al. Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial. Lancet Oncol 2025; 26: 629–40—In this Article, the first sentence of the fifth paragraph of the Discussion section should have read “Our translational research suggests that higher baseline expression of ERBB2, PD-1, and PD-L1, and ctDNA negativity are associated with pathological complete response after neoadjuvant pembrolizumab plus dual HER2 blockade.” This correction has been made to the online version as of Sept 29, 2025.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
